ANDROGEL (testosterone) by Besins Healthcare is androgen receptor agonists [moa]. Approved for hypogonadism. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ANDROGEL is a transdermal gel formulation of testosterone, an androgen receptor agonist approved in 2011 for hypogonadism and multiple other indications including muscle wasting, sexual dysfunction, and metabolic disorders. It works by binding to androgen receptors to restore testosterone levels and promote anabolic effects across tissues.
Product is in final 6 months before loss of exclusivity; commercial team is likely focused on transition planning and generic mitigation rather than growth initiatives.
Androgen Receptor Agonists
Androgen
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Puberty, Testosterone, and Brain Development
Worked on ANDROGEL at Besins Healthcare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
ANDROGEL is a mature product with minimal active hiring or career development opportunity, reflecting its imminent loss of exclusivity and declining commercial priority. Working on this product offers stability in established roles but limited growth, advancement, or transition to higher-impact assignments.